When someone feels worse after reducing an antidepressant, a clinician faces a question with consequences in both directions: is the original condition returning, or is this the body responding to the dose change?
Getting it wrong is costly either way. Reading withdrawal as relapse can commit a patient to medication they no longer need. Reading relapse as withdrawal can leave a treatable depressive episode untreated.
The difficulty is not a failure of clinical skill. It is built into the symptom overlap, because low mood, anxiety, irritability, poor concentration and sleep disturbance appear in both.
Nobody should stop or change an antidepressant based on this article. These decisions require a clinician, and abrupt discontinuation is the pattern most likely to cause problems.
The Symptoms and How Often They Occur
Discontinuation symptoms are documented and can occur regardless of the condition being treated, whether depression, an anxiety disorder, obsessive-compulsive disorder, or post-traumatic stress disorder.
A clinical review in BJPsych Advances by Mark Horowitz and David Taylor describes withdrawal symptoms as occurring in up to half of patients, more commonly after longer-term use and higher doses. Reported rates vary considerably across individual studies, with worsened mood reported in 22% to 45% of patients, anxiety in 12% to 42% and dizziness in 3% to 50%. Estimates of a full discontinuation syndrome, defined as four or more new or worsened symptoms after stopping, have ranged from 14% to 60%.
That range is itself informative. It reflects genuine differences in which drug was stopped, how quickly, and how symptoms were measured, and it means no single figure describes the risk.
In many cases symptoms last less than a week. In others they persist for weeks, months or longer, and there is currently no reliable way to predict who will experience them.
Most research has examined drugs that block the serotonin transporter, meaning SSRIs and SNRIs. Half-life matters: drugs that clear the body quickly produce more abrupt changes in blood levels and more pronounced symptoms.
The Features That Distinguish Them
Clinicians rely on several signals, none decisive alone.
Timing is the first. Withdrawal symptoms typically begin within days of a dose reduction, often two to four. Depression relapse follows a slower course, generally taking weeks to develop. The complication is that withdrawal onset can occasionally be delayed by several weeks as downstream effects accumulate, which the review's authors note is confusing for clinicians and patients alike.
Physical symptoms are the second and most useful. Dizziness, unsteadiness, nausea, sweating, muscle aches, flu-like sensations, and the electrical sensations patients describe as brain zaps are characteristic of withdrawal and are not features of depression. A clinical review identifies these as among the features that help separate the two.
Character is the third. Withdrawal symptoms often feel different from what a person experienced during their original illness, and patients who have tapered before frequently recognize the pattern.
Trajectory is the fourth, and it requires waiting rather than deciding immediately. Symptoms that peak early and then improve over three to four weeks support withdrawal. Symptoms that worsen from that peak, with deepening anhedonia and cognitive difficulty, point toward relapse.
Reinstatement functions as both treatment and partial diagnostic test. Withdrawal symptoms often resolve within one to three days of restoring an adequate dose, whereas depression does not respond that quickly to a medication already in the person's system. It is not conclusive, though. Reinstatement can fail when a taper has run too fast for too long or when the restored dose is too small, and a failed reinstatement does not by itself establish relapse.
Withdrawal is also misdiagnosed as other conditions entirely, including chronic fatigue syndrome, functional neurological disorder and various gastroenterological and neurological disorders, because its symptoms overlap with their diagnostic criteria.
The Research Problem This Creates
The overlap has consequences beyond individual care, and researchers have raised it about the evidence base itself.
Antidepressant discontinuation trials have been used to establish that these medications prevent relapse. In such trials, patients are randomized to continue medication or to stop, and relapse rates are compared.
If the stopping group experiences withdrawal symptoms that are then counted as relapse, the trial overstates the medication's protective effect. Researchers have noted that in many such studies the most common approach was abrupt cessation, with a weighted mean taper duration of about five days.
A preprint from researchers in Switzerland has estimated that a majority of symptom increases during antidepressant tapering relate to withdrawal rather than relapse, reporting that clinically relevant increases most often emerged following dose reduction below 75% of the minimum effective dose. That work has not completed peer review, and it was covered by an outlet that advocates for reform of psychiatric prescribing, context readers should weigh.
Attribution matters on the other side as well. The BJPsych Advances review is authored by researchers prominent in arguing that withdrawal has been understated, and its second author discloses grants and personal fees from several pharmaceutical companies. This is an active scientific disagreement rather than a settled finding.
What is not disputed is that discontinuation symptoms are real, can be significant, and were historically understated. The UK's Royal College of Psychiatrists acknowledged protracted withdrawal as a clinical entity in a 2019 position statement.
The Practical Implications for Patients
Tapering approaches have shifted in response. The Royal College of Psychiatrists has endorsed hyperbolic tapering, in which dose reductions become proportionally smaller as the dose falls, on the reasoning that receptor occupancy does not decline linearly with dose.
For patients considering a change, several things are worth raising with a prescriber. What taper schedule is planned, and over what period. Whether smaller final steps are available, since the last reductions are often hardest. What symptoms to expect and when. What the plan is if symptoms become difficult.
Timing matters too. Tapering during a stable period is generally preferable to attempting it during acute stress. MedicalDaily has covered how virtual mental health care has expanded, which affects how often prescribers and patients meet.
Nobody should reduce or stop an antidepressant independently. Abrupt cessation produces the most severe symptoms, and stopping without a plan removes the monitoring that distinguishes withdrawal from relapse.
Anyone experiencing worsening depression, hopelessness, or thoughts of self-harm during a medication change should contact their prescriber promptly rather than waiting for a scheduled appointment. The 988 Suicide and Crisis Lifeline is available by call or text at any hour, and is free and confidential. MedicalDaily has covered where community mental health care is expanding.
Key Questions Answered
What are antidepressant discontinuation symptoms? Symptoms that can occur when an antidepressant is reduced or stopped, including worsened mood, irritability, anxiety, dizziness and headache, along with physical symptoms like nausea, sweating and electrical sensations described as brain zaps.
How common are they? A clinical review describes them as occurring in up to half of patients, more often after longer use and higher doses. Estimates of a full discontinuation syndrome range from 14% to 60% across studies, reflecting differences in drug, taper speed and measurement.
How long do they last? Often less than a week. In some people they persist for weeks, months or longer. There is no reliable way to predict who will experience them.
How do clinicians tell withdrawal from relapse? Withdrawal typically begins within days of a dose change, includes physical symptoms depression does not produce, often feels different from the original illness, and frequently improves within days if the prior dose is restored. Onset can occasionally be delayed by weeks, and a failed reinstatement does not by itself prove relapse.
Why does this matter for research? Trials establishing that antidepressants prevent relapse often stopped medication abruptly. If withdrawal symptoms were counted as relapse, those trials would overstate the protective effect. This is an active scientific debate with advocacy and industry disclosures on both sides.
What is hyperbolic tapering? An approach in which dose reductions become proportionally smaller as the dose falls, endorsed by the UK's Royal College of Psychiatrists, based on how receptor occupancy changes with dose.
Should anyone stop an antidepressant on their own? No. Abrupt cessation produces the most severe symptoms and removes the monitoring needed to distinguish withdrawal from relapse. Anyone experiencing worsening depression or thoughts of self-harm during a change should contact their prescriber promptly. The 988 Suicide and Crisis Lifeline is available around the clock.
